Lasoprol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lasoprol

What is Lasoprol?

Lasoprol is a pharmaceutical medication belonging to a class of drugs known as proton pump inhibitors (PPIs). It contains the active substance lansoprazole, which is primarily used to manage conditions related to excessive gastric acid production.

Mechanism of Action

The medication works by targeting the gastric proton pumps found within the parietal cells of the stomach lining. These pumps are responsible for the final stage of acid secretion. By inhibiting these pumps, Lasoprol effectively reduces the amount of acid the stomach produces. This reduction in acidity helps to create an environment conducive to the healing of the esophageal and gastric mucosa.

Primary Therapeutic Applications

Lasoprol is utilized in several clinical contexts where acid reduction is beneficial for recovery or symptom management:

  • Gastric and Duodenal Ulcers: It is used to treat and help prevent the recurrence of ulcers in the stomach and the upper part of the small intestine.
  • Gastroesophageal Reflux Disease (GERD): The medication is used to manage symptoms such as heartburn and acid regurgitation, and to treat erosive esophagitis, which is inflammation of the food pipe caused by acid reflux.
  • Zollinger-Ellison Syndrome: It is employed to manage rare conditions involving pathological hypersecretion of gastric acid.
  • Eradication of Helicobacter pylori: In combination with appropriate antibiotics, it is used to eliminate H. pylori infections, which are a common cause of stomach ulcers.

General Characteristics

As a PPI, Lasoprol is typically formulated to be acid-stable, ensuring that the active ingredient is released in the intestines rather than the stomach to allow for proper absorption. It is intended for the systematic management of acid-related disorders and is used to provide relief from discomfort associated with gastric hyperacidity.

Regulatory References

  1. NIH MedlinePlus
  2. Lansoprazole
  3. Proton Pump Inhibitors (PPIs) Information
  4. Lansoprazole Prodrug

What side effects are possible with Lasoprol?

Possible Side Effects and Safety Information

The officially documented adverse effects of Lasoprol (Lansoprazole) are classified by regulatory authorities based on the frequency of occurrence and the affected organ system. This information is derived strictly from government sources like the FDA and EMA to establish the medicine's formal safety profile.


Frequency-Classified Adverse Reactions

Adverse reactions are formally categorized according to regulatory frequency standards:

  • Common Reactions (affecting 1 to 10 users in 100): These often involve the Gastrointestinal System, including diarrhea, constipation, nausea, abdominal pain, and flatulence. Headache and dizziness are also classified as common.
  • Uncommon Reactions: These include muscle pain (myalgia), joint pain (arthralgia), rash, and elevated liver enzymes.
  • Rare and Very Rare Reactions: These effects involve multiple systems, including rare hematological changes such as thrombocytopenia and leukopenia. Very rare documented severe reactions include Agranulocytosis and severe skin reactions like Stevens-Johnson Syndrome (SJS).

Serious Safety Patterns and Considerations

Regulatory documents highlight specific safety considerations associated with use:

  • Duration-Related Effects: Prolonged use of Lansoprazole (typically over one year) has been associated with specific safety patterns, including the potential for Vitamin B12 deficiency and Hypomagnesemia (low magnesium levels). Long-term use is also associated with an increased risk of osteoporosis-related bone fractures.
  • Population Notes: Caution is advised for individuals with severe hepatic impairment due to the potential for increased systemic exposure to the medicine.
  • Infection Risk: Official labeling notes an increased risk of gastrointestinal infections caused by bacteria, including Clostridium difficile-associated diarrhea.

This information is presented solely to describe the officially documented safety characteristics of the medicine and is not intended as medical advice or instruction.

Overdose and Emergency Response

Overdose and When to Seek Help

Official government regulatory information defines the management and expected outcomes following an overdose of Lasoprol.


Documented Overdose Manifestations

Experience with accidental or intentional overexposure suggests that toxicity is generally low. The specific symptoms reported in regulatory documentation following high doses primarily involve the gastrointestinal and nervous systems. These documented manifestations include:

  • Diarrhea
  • Abdominal pain
  • Nausea
  • Headache
  • Constipation

Regulatory authorities note that single exposures up to 600 mg have been reported in humans without resulting in adverse clinical effects.


Immediate Actions and Management

In all cases of suspected overdose, the official regulatory instruction is to seek emergency medical attention or contact a Poison Control Center immediately.

Management constraints noted in official labeling:

Management Feature Official Regulatory Statement
Recommended Action Symptomatic and supportive care is the standard management approach.
Drug Removal Constraint The drug is highly protein-bound; therefore, hemodialysis is not expected to be an effective method for removal in an overdose situation.

The official overdose profile emphasizes immediate professional consultation due to the low but present risk, while defining the necessary supportive care and noting specific constraints on drug elimination procedures.

Therapeutic Uses of Lasoprol

Quick Facts

  • Acid Reflux and Heartburn: Manages symptoms of acid reflux and frequent heartburn.
  • Gastroesophageal Reflux Disease (GERD): Supports the management of GERD.
  • Esophageal Damage: Provides support for healing inflammation or damage to the esophagus caused by stomach acid (erosive esophagitis).
  • Ulcers: Assists in the treatment and prevention of gastric (stomach) and duodenal ulcers.
  • Excessive Acid Secretion: Manages conditions associated with the stomach producing too much acid, such as Zollinger-Ellison syndrome.

What Lasoprol Treats: Main Uses and Benefits

Lasoprol is a medication prescribed to manage conditions where there is an increased production of stomach acid. Its primary therapeutic domains involve supporting the healing process and providing symptom control across various digestive health issues. The medication assists in managing the discomfort associated with frequent heartburn and acid reflux in adults.

It is an established therapeutic option for addressing Gastroesophageal Reflux Disease (GERD). For individuals experiencing damage to the lining of the esophagus due to acid backflow, Lasoprol offers support for the healing of erosive esophagitis. Additionally, it is used to assist in the treatment of both duodenal ulcers and gastric ulcers (stomach ulcers).

In specific contexts, Lasoprol may be utilized in combination with other therapeutic agents to help clear Helicobacter pylori (H. pylori) infections, which are often associated with the development of ulcers. The medication is also available for use in the long-term management of conditions characterized by highly excessive stomach acid secretion, such as Zollinger-Ellison syndrome.

Eligibility and Restrictions for Use

Lasoprol (Lansoprazole) eligibility is determined by specific population restrictions and absolute contraindications defined by regulatory authorities.

Who Must Not Use Lasoprol (Contraindications)

Use is contraindicated if a patient has a known severe hypersensitivity to the drug or any component of the formulation. Co-administration is also prohibited with medicines containing rilpivirine or atazanavir.

Population Restrictions and Conditional Use

Population/Condition Regulatory Eligibility Status
Infants (Under 1 Year) Not recommended or not established for use.
Children & Adolescents (1 Year and Older) Established for specific, limited durations and indications.
Severe Hepatic Impairment Conditional use requiring a potential dose adjustment or restriction.
Pregnancy Not recommended (precautionary principle).
Phenylketonuria (PKU) Restricted eligibility for Orally Disintegrating Tablet (ODT) formulations.

Before starting Lasoprol, it is a regulatory requirement to exclude the presence of gastric malignancy, as the medicine may mask symptoms. Use in patients with renal impairment generally does not require a dose adjustment. For nursing mothers, use is conditional, requiring an assessment of risks versus benefits to the infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Lasoprol (Lansoprazole) based on its effect on gastric pH and its metabolism via the CYP enzyme system. Co-administration constraints are classified as prohibited, requiring close monitoring, or requiring specific timing separation.

Official Co-administration Restrictions

Co-administration with the antiretrovirals Rilpivirine and Atazanavir is generally not recommended or is formally contraindicated due to the risk of significantly decreased plasma concentrations of the antiretroviral agent. This is a functional interaction stemming from Lasoprol's acid-suppressing activity, which also affects other medicines requiring low gastric pH for absorption, such as Ketoconazole and certain oncology drugs.

Pharmacokinetic and Timing Requirements

Lasoprol is primarily metabolized by the CYP2C19 and CYP3A4 enzymes, and it acts as a weak inhibitor of CYP2C19. This may necessitate monitoring when used with sensitive substrates like Warfarin (due to increased INR risk), Tacrolimus, or Cilostazol. Conversely, strong inducers like Apalutamide are documented to decrease Lasoprol's exposure. The binding agent Sucralfate requires administration to be separated from Lasoprol by at least 30 minutes to ensure adequate absorption of Lasoprol. Specific interaction cautions related to slower clearance are noted for patients with severe hepatic impairment.

Mechanism of Action

Lasoprol functions by binding selectively to the P2Y6 receptor on the surface of osteoclast progenitor cells. This selective binding event initiates an inhibitory signal cascade within the cell, which prevents the subsequent differentiation and maturation of these precursor cells into active, multinucleated osteoclasts.

This action regulates the expression of key enzymatic factors, including cathepsin K and matrix metalloproteinases (MMPs), within the pre-osteoclast population. The resulting reduction in the number of functional, bone-resorbing osteoclasts decreases the overall rate of bone matrix degradation.

Downstream of P2Y6 activation, Lasoprol modulates the RANK/RANKL/OPG axis by influencing the release of osteoprotegerin (OPG). The final consequence of these molecular events is a direct reduction in the bone resorption rate at the cellular and tissue level, which influences bone mineral content and density.

Dosage and Administration Information

How to Use Lasoprol — Administration Guidelines

Lasoprol (lansoprazole) administration follows standardized guidelines to ensure correct use. The drug is available in Delayed-Release Capsules, Orally Disintegrating Tablets (ODT), and Intravenous (IV) injection.


Dosing and Timing

Administration is generally Once Daily and must be taken before a meal (e.g., 30 minutes before breakfast). Dosing varies widely by condition, ranging from 15 mg once daily to 30 mg twice daily for H. pylori eradication. For pathological hypersecretory conditions, doses up to 120 mg daily may be required, which must be divided.

Condition Example Standard Adult Dosing Frequency/Duration
Active Duodenal Ulcer 15 mg Once Daily (4 weeks)
Erosive Esophagitis (EE) 30 mg Once Daily (up to 8 weeks)
H. Pylori Eradication 30 mg (with antibiotics) Twice Daily (10–14 days)

Administration Technique

Capsules must be swallowed whole; they must not be crushed, chewed, or split. If swallowing difficulty exists, the capsule may be opened, and the contents (intact pellets) can be sprinkled onto soft food (e.g., one tablespoon of applesauce) or mixed with certain juices (e.g., apple juice) and swallowed immediately.

ODTs are placed on the tongue, allowed to dissolve, and then swallowed. They should also not be crushed or chewed.

IV Injection is an alternative route for patients unable to take oral forms but is limited to seven days of use.


Special Populations and Missed Dose

Pediatric patients (ages 1–17) have specific weight- or age-based dosing regimens. Patients with moderate or severe liver impairment may require a dose reduction. If a dose is missed, it should be taken as soon as remembered; however, if it is near the time of the next dose, the missed dose must be skipped to avoid taking two doses at once.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lasoprol


Evidence for use in Managing Gastroesophageal Reflux Disease (GERD) and Esophagitis

Research into Lasoprol's use for managing Gastroesophageal Reflux Disease (GERD) and frequent heartburn has included short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how outcomes related to physical discomfort change over defined time intervals. Research describes that these studies monitored the frequency of heartburn and changes in symptom severity scores over periods typically lasting up to eight weeks. Studies conducted during periods of increased symptom activity reported measurements of a change in the frequency of heartburn episodes, suggesting that administering the medicine was associated with a pattern of changes in measured symptom scores when compared to initial measurements. The research for this condition relies mainly on high-quality study designs like Randomized Controlled Trials. However, research for Erosive Esophagitis healing focuses mainly on short-term outcomes, and extended follow-up data are limited.


Evidence for use in Treating Gastric and Duodenal Ulcers

Lasoprol was studied for its use in promoting the healing of both gastric (stomach) and duodenal (small intestine) ulcers. Research examined its role using short-term RCTs that compared the medicine against a placebo or older treatments. These studies explored outcomes linked to inflammatory or irritative states, with primary outcomes being the endoscopic healing rate of the ulcers. Reports from these studies describe the proportion of ulcers that were confirmed as healed by endoscopy after the treatment period, and the timing and extent of changes in ulcer pain reported among the studied patients. The research for this area also relies heavily on high-quality study designs. However, much of the foundational data for ulcer healing is derived from studies conducted some time ago, and comparative evidence against the newest acid-suppressing compounds is lacking.


Long-term Study Designs and Follow-up Data

Research has explored the medicine's sustained use, especially following the healing of Erosive Esophagitis and for managing Pathological Hypersecretory Conditions like Zollinger-Ellison Syndrome. For Esophagitis maintenance, Long-term RCTs provided evidence, reporting measurements of the proportion of patients who remained recurrence-free over six to twelve months. Researchers note that these follow-up durations were limited for evaluating outcomes over a patient's lifetime. Due to the rarity of conditions like Zollinger-Ellison Syndrome, the evidence base relies mainly on Observational Studies and Case Series, where reports described patterns of acid output measurements when high doses of the medicine were administered over extended periods. Certainty remains low compared to evidence for common indications, and long-term effects are not fully established by controlled research.

Key Studies & References

  1. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer

Frequently Asked Questions (FAQ)

Common questions about Lasoprol (FAQ)

Q: How long can a person stay on Lasoprol medication?

A: Studies and official information indicate that while many indications for Lasoprol are managed short-term, some long-term maintenance use is studied for periods up to 12 months or longer. For specific, rare conditions, continuous use may be necessary. In all cases, official regulatory documents state the importance of using the lowest effective dose.


Q: Is Lasoprol considered a long-term medication?

A: Official information describes Lasoprol as a medicine prescribed for both short-term use, which is generally up to eight weeks for healing, and for long-term use for certain chronic conditions. Extended use is typically reserved for maintenance therapy for severe esophageal issues or rare hypersecretory conditions.


Q: Is it okay to take Lasoprol with food?

A: Official product information describes that Lasoprol is administered at least 30 minutes before a meal or snack. This timing is important because food can interfere with the way the medicine is absorbed, which may impact how well it works.


Q: Is Lasoprol a high-risk medication?

A: Regulatory documents state that adverse effects are typically described as mild and reversible in official documentation. However, official safety warnings have been issued regarding potential risks associated with prolonged use (typically over one year), including an increased risk of bone fractures and a specific type of gastrointestinal infection.


Q: If I feel better, can I stop taking Lasoprol immediately?

A: Official regulatory documents describe that patients on continuous therapy undergo periodic evaluation to determine the continued need for the medicine. The process of discontinuing the medication often involves a gradual reduction of the dose or a switch to an 'as needed' regimen, according to clinical literature.


Q: Is Lasoprol the same kind of medication as [similar drug name]?

A: Lasoprol, containing the active ingredient Lansoprazole, is officially classified as a Proton Pump Inhibitor (PPI). Its function is to reduce stomach acid production. Studies and official information describe its general effectiveness and safety profile as similar to other medicines in the same PPI drug class.


Q: How long does it typically take to notice the effects of Lasoprol?

A: Official information indicates that the onset of symptomatic relief may be observed within 2 to 3 days of beginning treatment. However, official information indicates that it can take up to four weeks for the medicine to achieve its maximum effect in fully controlling acid-related symptoms.


Q: Can Lasoprol be taken with common over-the-counter pain relievers?

A: Official information indicates there is no known interaction documented between Lansoprazole and Acetaminophen. However, the potential for co-administration with non-steroidal anti-inflammatory drugs (NSAIDs) is an interaction that may necessitate specific monitoring.


Q: Will Lasoprol affect my ability to drive or operate machinery?

A: The official adverse effects list includes dizziness and headache as common reactions. Official safety information indicates that these symptoms may influence the ability to drive or operate machinery.


Q: Are there specific foods or beverages to avoid while using Lasoprol?

A: Official guidance associated with the conditions Lasoprol treats often suggests avoiding or limiting factors that can aggravate symptoms. These often include alcohol, coffee, chocolate, and fatty foods.


Q: Can older adults use Lasoprol safely?

A: Official criteria for older adults describe that scheduled use beyond eight weeks for uncomplicated conditions should generally be avoided. This is due to the potential for increased risk of bone loss and certain infections in this population.


Q: Are there any known issues when combining Lasoprol with alcohol?

A: Alcohol is not listed as a formal contraindication in official documents. However, general health guidance associated with the treated conditions suggests that limiting or avoiding excessive alcohol intake may help manage symptoms.


Q: Is Lasoprol known to interact with birth control pills?

A: Clinical studies have specifically investigated the co-administration of Lansoprazole with low-dose oral contraceptives. These studies found that Lasoprol did not significantly affect the absorption of the hormonal components of birth control pills.


Q: Can Lasoprol cause changes in sleep patterns?

A: Insomnia (trouble sleeping) is listed as a documented adverse effect of Lasoprol in official regulatory safety summaries. This indicates a potential for the medicine to affect sleep patterns.


Q: Does taking Lasoprol require regular blood tests?

A: Regular monitoring is recommended in official documents for certain situations. This includes monitoring of certain parameters, such as magnesium levels in patients on long-term therapy or monitoring the INR in patients also taking Warfarin.


Q: Can Lasoprol make me feel tired throughout the day?

A: Fatigue (feeling tired) is listed as a reported adverse effect of Lasoprol in official safety summaries. If this symptom is experienced, it is documented as a possible effect of the medication.


Q: Are there specific warning signs for a serious reaction to Lasoprol?

A: Official documentation describes that medical attention should be sought if signs of liver injury are experienced, such as yellowing of the skin or eyes or loss of appetite. Attention is also advised for symptoms associated with severe skin reactions like fever, rash, and joint pain.


Q: Can I take vitamins or supplements while on Lasoprol?

A: Regulatory safety information notes that all supplements, vitamins, and minerals should be disclosed to a healthcare provider. This is due to the potential for these products to interact with the medication.


Q: Does Lasoprol interact with natural health products like herbal teas?

A: Regulatory safety information notes that all herbal products should be disclosed to a healthcare provider. This is due to the potential for these products to interact with the medicine.


Q: Is Lasoprol prescribed for anxiety or only for physical conditions?

A: The official indications for Lasoprol are strictly limited to physical conditions related to acid suppression, such as ulcers, GERD, and Zollinger-Ellison syndrome. Anxiety is not listed as an approved treatment indication.


Q: Is there any risk of dependency or withdrawal when stopping Lasoprol?

A: Regulatory and evidence reviews describe the potential for a temporary phenomenon called rebound hypersecretion of stomach acid when the medicine is stopped. This may cause a temporary recurrence or worsening of the original acid-related symptoms.


Q: Can Lasoprol impact my mood or mental state?

A: Depression and confusion are listed as known adverse effects in official safety summaries. These documented effects indicate a potential for the medicine to impact a person's mood and mental state.


Q: Are there any specific concerns about taking Lasoprol before surgery?

A: While general surgery is not specifically addressed, some official guidelines for certain diagnostic procedures, such as an endoscopy, recommend stopping the medicine several days beforehand as a 'washout period' to avoid masking symptoms.


Q: Why is it important to know who cannot use Lasoprol?

A: Official documents highlight the requirement to first exclude the presence of gastric malignancy before beginning the medicine. This is because Lasoprol may mask the symptoms of that underlying condition.


Q: Can I use Lasoprol if I have a history of breathing problems?

A: The official safety profile lists the potential for a small increased risk of community-acquired pneumonia in certain high-risk groups. The medicine has been studied in older patients with COPD (a breathing problem), indicating it is not an absolute contraindication for this group, but caution is warranted.

How should Lasoprol be stored and disposed of?

Storage Conditions

Lasoprol (Lansoprazole) must be stored at controlled room temperature, specifically between 20°C and 25°C (68°F and 77°F). It is mandatory to protect the medicine from moisture and keep it away from high heat and humidity. The product must remain in its original container, which must be kept tightly closed to maintain the stability of the delayed-release formulation. As a standard safety requirement, Lasoprol must be kept out of the sight and reach of children.

Disposal Instructions

Any unused or expired Lasoprol must be disposed of according to local regulatory requirements. Official guidelines recommend utilizing a community drug take-back program where available. The medicine should not be flushed down the toilet or discarded in household trash unless explicitly instructed to do so by a healthcare provider or local waste service.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lasoprol found in:

A-Z Index: